RXST: Bull Flag detected on 27 Jul 2026

RXST is forming a bull flag pattern with a structure score of 14.5/15, indicating a well-defined consolidation phase after prior bullish movement. At $5.19, the stock is trading between key support at $5.06 and resistance at $5.93. The breakout score of 12.6/13 and volume score of 11.4/12 reflect moderately strong pattern conditions, though current volume of 842,702 shares represents only 53% of the 20-day average, suggesting below-average participation. The overall score of 79.5/98 and 78.65% win probability indicate a credible setup. RSI at 47.68 shows neutral momentum—neither overbought nor oversold—providing room for continuation.

RxSight announced on July 6, 2026, a strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses, a catalyst that has reshaped the company's growth narrative. Q2 2026 total revenue is expected at $32 to $34 million, including $5 to $7 million from the Alcon collaboration, with product sales about $27 million driven by 24,917 Light Adjustable Lens units. Critically, the company cut its full-year 2026 sales guidance below previous guidance of $120 to $135 million to $110 to $120 million, signaling slower standalone unit growth. However, on July 24, 2026, RxSight appointed Aziz Mottiwala as new President and Chief Executive Officer, injecting fresh leadership. Cash position of approximately $209 million as of June 30, 2026 provides balance sheet stability, but the margin of sales guidance miss explains why the stock has declined 27.92% over three months despite the Alcon deal.

A successful breakout above $5.93 resistance would target the conservative price target of $5.36—a modest 3.3% move from current levels. Volume confirmation is critical; since current volume runs at 53% of average, the breakout needs material participation above the 20-day average to validate the pattern. The invalidation level sits at key support $5.06; a close below this level would negate the bull flag setup and signal continuation of the downtrend. The 78.65% win probability reflects historical reliability of bull flags when properly formed, though the measured move is relatively constrained given the flag's tight consolidation range.

Earnings results are imminent—the company plans to report financial results for the second quarter of 2026 after the market close on Wednesday, August 5, 2026—only nine trading days away, creating event risk. The 3.1% 2-week gain masks severe 3-month weakness (-27.92%), indicating sustained selling pressure despite the Alcon collaboration. Leadership transition executed just three days ago on July 20-24 introduces execution uncertainty around the new CEO's strategic direction. Critically, the company cut 2026 sales guidance, suggesting the market has already repriced expectations lower; further weakness in unit sales or device placements in Q2 could trigger additional downside. The Health Care sector is bullish (regime score +0.58), but RXST's beta of 0.33 and below-average volatility (8.29% ATR) suggest the stock is moving independently—decoupled from sector momentum—a warning sign of company-specific headwinds.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.